P3T PA (pulmonary angiography), from Medrad, is a personalized contrast-dosing software that increases the percentage of diagnostic-quality CT pulmonary angiography (CTPA) studies to rule out pulmonary embolism (PE).
Researchers have concluded that suboptimal CTPA interpretations to rule out PE can substantially impact healthcare resource utilization and increase healthcare costs. With 30 percent of their CTPA studies showing suboptimal results, these patients were subjected to additional imaging studies and/or received medical therapy. Some patients were admitted to the hospital for further PE diagnosis considerations. None of the additional treatments or imaging modalities yielded a diagnosis of PE.
P3T PA fits into the established workflow and offers flexibility and efficiency in optimizing each patient’s contrast dose -- especially when operating higher-speed scanners. The P3T algorithm tailors each patient’s contrast protocol based on technologists’ touch-screen responses to unique clinical concerns, study requirements and the scanning equipment used.
It is the third module in the company’s P3T software line, which also includes cardiac and abdominal CT modules that automate each patient’s optimal contrast dose for studies addressing these areas of the anatomy.
For more information: www.medrad.com
October 28, 2026 
